Key result
Intrathecal administration of 10 µg dexmedetomidine with ropivacaine in total knee arthroplasty provided rapid block onset, extended sensory block up to 12 hours, and favorable early postoperative analgesia.
Why the study?
A key limitation of spinal anesthesia in total knee arthroplasty is the relatively short duration of local anesthetics, prompting the use of intrathecal adjuvants such as dexmedetomidine to extend block duration and enhance postoperative pain management.
Does intrathecal dexmedetomidine combined with ropivacaine improve sensory and motor block duration and postoperative analgesia in patients undergoing total knee arthroplasty?
Observational (n=20)
No
Does intrathecal dexmedetomidine combined with ropivacaine improve sensory and motor block duration and postoperative analgesia in patients undergoing total knee arthroplasty?
Intrathecal dexmedetomidine as an adjuvant to ropivacaine in spinal anesthesia for TKA provides prolonged sensory and motor block with effective early postoperative analgesia and manageable hemodynamic changes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for intrathecal dexmedetomidine in TKA; larger RCTs needed before any practice consideration.
Spinal anesthesia is widely used in total knee arthroplasty (TKA) because it provides reliable block characteristics and favorable perioperative outcomes. However, a key limitation is the relatively short duration of local anesthetics, which may require additional analgesia or a switch to general anesthesia. To address this, intrathecal adjuvants are used to extend the duration of the block and enhance postoperative pain management. Dexmedetomidine, a highly selective α₂-adrenergic agonist, has demonstrated sedative and analgesic properties without respiratory depression, making it an attractive alternative to opioids such as fentanyl. In this case series, 10 µg of intrathecal dexmedetomidine was combined with ropivacaine in 20 patients undergoing TKA. Outcomes assessed included onset and regression of sensory and motor block, postoperative pain scores, and hemodynamic stability. Dexmedetomidine produced a rapid block onset, extended sensory block lasting up to 12 hours in some patients, and a predictable pattern of motor regression. Postoperative analgesia was favorable, with most patients remaining pain-free for the first six hours and reporting only mild discomfort at 12 hours. Hemodynamic changes observed included reductions in heart rate (HR) and mean arterial pressure (MAP), with some patients requiring vasopressor support, though no serious adverse events occurred. Our findings align with randomized controlled trials (RCTs) and meta-analyses indicating that intrathecal dexmedetomidine extends block duration, reduces the need for postoperative analgesics, and offers a favorable efficacy and side-effect profile compared to fentanyl. This case series adds to the existing body of evidence by presenting real-world clinical data on the use of intrathecal dexmedetomidine as an adjuvant to ropivacaine in elderly patients undergoing TKA. It demonstrates the adjuvant's safety, hemodynamic stability, and analgesic effectiveness in a routine hospital setting, supporting the applicability of findings from controlled trials to everyday anesthetic practice. Further large-scale studies are needed to refine dosing strategies and evaluate long-term outcomes in orthopedic populations.
No takes yet. Share an insight, caveat, or question.
Ioannidis et al. (2025) conducted an observational in Total knee arthroplasty (n=20). Intrathecal dexmedetomidine with ropivacaine was evaluated on Sensory and motor block characteristics, postoperative pain scores, and hemodynamic stability. Intrathecal administration of 10 µg dexmedetomidine with ropivacaine in total knee arthroplasty provided rapid block onset, extended sensory block up to 12 hours, and favorable early postoperative analgesia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: